Alnylam Pharmaceuticals (ALNY) PT Raised to $180 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $165.00 -5.17%
Rating Summary:
27 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
27 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Needham & Company analyst Alan Carr raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $180.00 (from $160.00) while maintaining a Buy rating.
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Freedom Broker
- Oil States International (OIS) PT Lowered to $11 at Raymond James
- Digital Realty Trust (DLR) PT Lowered to $227 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
